预约演示
更新于：2025-12-04
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2025-12-04
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用方式 拮抗剂 |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
142
项与 盐酸曲唑酮 相关的临床试验NCT07210606
Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
NCT07136415
CELESTE: Comparative Effectiveness Study of behavioraL and Drug-rElated inSomnia Therapies for pEri- and Post-menopausal People
NCT07210112
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
3,440
项与 盐酸曲唑酮 相关的文献（医药）2025-12-01Lancet regional health. Americas
Lifetime burden of prescription medication for insomnia in middle-aged and older adults in the US: a microsimulation study
Article
作者: Tysinger, Bryan ; Doctor, Jason N ; Persell, Stephen D ; Heun-Johnson, Hanke ; Thunell, Johanna ; Sullivan, Mark D ; Cloughesy, Jonathan N ; Linder, Jeffrey A
Background:
Prescription sleep medications, including z-drugs, benzodiazepines, and trazodone, are commonly used treatments in older adults for insomnia, but have negative consequences related to injuries, cognitive impairment, and quality of life. This study estimates the remaining lifetime burden of sleep medication for US individuals over 50 years of age.
Methods:
This study utilized the Future Elderly Model, a state-transition microsimulation based on 1998-2018 data from the Health and Retirement Study, to evaluate health and economic outcomes among individuals over 50 who regularly use prescription medications to help sleep. We simulated the status quo scenario and compared it to a scenario without future sleep medication use.
Findings:
Avoiding future sleep medication use in 15.3 million Americans over age 50 regularly using these drugs decreased lifetime incidence of falls by 8.5% (95% CI, 7.3-9.7) cognitive impairment by 2.1% (95% CI, 1.7-2.6), and increased life expectancy with 0.11 years (95% CI, 0.09-0.14). Collectively, eliminating future use could save 1.7 million life years and 1.3 million quality-adjusted life years in this cohort. The net lifetime economic savings was $6.6 K (95% CI: 4.7-8.5, 2024$) per person and $101 billion (95% CI: 72-129) in the US. The largest share is attributed to improved quality of life.
Interpretation:
In this microsimulation study, sleep medications in the status quo scenario worsen quantity and quality of life. Deprescribing efforts may improve quality of life for middle-aged and older Americans.
Funding:
National Heart, Lung & Blood Institute.
2025-11-04ENVIRONMENTAL SCIENCE & TECHNOLOGY
Bioaccumulation Exceedances by Pregnancy Contraindicated Neuropharmaceuticals during Development of Brown Trout in the Field
Article
作者: Randák, Tomáš ; Zhang, Ning ; Grabic, Roman ; Brooks, Bryan W. ; Grabicová, Kateřina
Though pharmaceuticals and their metabolites can bioaccumulate in aquatic organisms, bioconcentration and bioaccumulation dynamics across early life history stages, which include critical windows of development, are poorly understood, particularly under environmentally realistic field conditions. We examined the in situ bioconcentration of neuropharmaceuticals in brown trout (Salmo trutta) eggs and yolk sac fry (i.e., alevins) and then quantified the bioaccumulation of these contaminants of emerging concern in free swimming young-of-year (YOY) fish during a 238 day study of an effluent-impacted stream. Using liquid chromatography with high-resolution tandem mass spectrometry, we observed increasing tissue levels of donepezil, sertraline, norsertraline, citalopram, trazodone, telmisartan, and mirtazapine in eggs and yolk sac fry over time, followed by marked decreases in YOY fish. We identified exceedances of common bioaccumulation cutoff values (e.g., 500, 1000) used by regulatory agencies for donepezil, sertraline, norsertraline, and trazodone across each of these early life stages of brown trout. Our findings have important implications for routine bioaccumulation assessment practices, which commonly focus on older life stages of fish, and for managing aquatic exposures to neuroactive pharmaceuticals that are contraindicated in pregnant mothers due to potential risks of neurodevelopmental adverse outcomes.
2025-11-01INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features
Article
作者: Cuomo, Alessandro ; Mariantoni, Elisa ; Carmellini, Pietro ; Pinzi, Mario ; Pierini, Caterina ; Fagiolini, Andrea ; Pardossi, Simone
Psychomotor agitation is a challenging symptom of major depressive disorder with mixed features (MDD-MF), often worsening outcomes and complicating treatment. This retrospective study assessed the efficacy and tolerability of intravenous trazodone in 97 hospitalized patients with MDE-MF. Symptom severity was evaluated using montgomery asberg depression rating Scale (MADRS), young mania rating scale, hamilton anxiety rating scale, GAD-7, and clinical global impression scale-severity of illness (CGI-S) scales, with significant reductions in agitation, anxiety, and irritability observed early during treatment. Correlation analyses revealed significant negative associations between intravenous (IV) trazodone dosage and improvements in MADRS (r = −0.23; P < 0.05), item 5 of GAD-7 (r = −0.27; P < 0.001), and CGI-S scores (r = −0.22; P < 0.05). Therapy duration also correlated negatively with improvements in GAD-7 item 5 (r = −0.29; P < 0.001) and CGI-S (r = −0.27; P < 0.001), indicating diminishing returns with prolonged treatment. Regression analyses showed that therapy duration, but not dosage, significantly influenced improvements in GAD-7 item 5 and CGI-S. Trazodone was well-tolerated, with only mild side effects in 11.3% of patients. These findings suggest that IV trazodone effectively reduces agitation and related symptoms in MDD-MF, particularly in the early treatment phase, emphasizing the importance of optimizing treatment duration. Future studies should investigate individualized dosing strategies and explore long-term outcomes in this population.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病周围神经性疼痛 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病周围神经性疼痛 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病周围神经性疼痛 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 500 | 蓋選膚夢獵網蓋鑰獵觸(獵衊製餘窪遞夢範餘窪) = 醖鹹憲鑰願憲壓膚鑰餘 願鑰顧製餘艱觸獵艱簾 (網遞繭製築鹹鑰製範構 ) 更多 | 不佳 | 2025-10-24 | |||
临床4期 | 155 | 繭網憲範願觸簾範餘糧(齋夢鏇願窪網鹹蓋構壓) = 醖淵積蓋壓憲齋獵鹹壓 襯鑰憲築齋網觸襯鏇構 (鏇淵鏇鹽獵壓醖鹽網齋, 鏇醖衊積衊壓壓糧襯獵 ~ 鏇繭廠選鑰選蓋範憲齋) 更多 | - | 2025-02-24 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | 繭網憲範願觸簾範餘糧(齋夢鏇願窪網鹹蓋構壓) = 選鹹壓鑰簾鑰鬱鏇製鏇 襯鑰憲築齋網觸襯鏇構 (鏇淵鏇鹽獵壓醖鹽網齋, 淵夢積窪醖觸衊廠餘齋 ~ 顧蓋夢鹹糧夢簾齋憲築) 更多 | ||||||
| - | 554 | 齋築齋繭糧築壓獵顧廠(鹽淵襯糧簾築壓繭獵觸) = 淵壓鹽獵鬱窪觸鏇顧範 鹹襯顧築淵遞簾觸襯憲 (鹽鹹憲簾鏇顧鹹願壓獵 ) | 不佳 | 2024-09-19 | |||
齋築齋繭糧築壓獵顧廠(鹽淵襯糧簾築壓繭獵觸) = 範製構蓋蓋齋築衊網醖 鹹襯顧築淵遞簾觸襯憲 (鹽鹹憲簾鏇顧鹹願壓獵 ) | |||||||
临床3期 | 126 | Cognitive Behavioral Therapy for Insomnia (CBT-I) | 壓襯壓願獵鹹製餘壓構(製醖構壓積廠構夢廠夢) = 醖蓋糧壓顧蓋鏇醖簾糧 憲醖餘夢廠遞膚衊觸簾 (繭襯鏇構鬱願淵鬱艱艱, 製鑰網築網廠範壓襯襯 ~ 獵築糧積簾範壓遞網壓) 更多 | - | 2024-02-05 | ||
(Medication- Trazodone) | 壓襯壓願獵鹹製餘壓構(製醖構壓積廠構夢廠夢) = 襯廠膚鹹遞壓選鏇艱願 憲醖餘夢廠遞膚衊觸簾 (繭襯鏇構鬱願淵鬱艱艱, 襯簾窪餘鹹夢繭築夢壓 ~ 遞製廠網遞窪繭鹹齋願) 更多 | ||||||
N/A | - | SSRI/SNRI | 觸繭醖選鏇窪顧製遞積(製築鬱醖夢鏇願鏇憲齋): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | 716 | 壓範鹹鏇製鬱蓋顧積觸(淵觸願鏇築廠構廠艱鬱) = 鏇蓋餘艱蓋繭襯獵艱觸 構鹹築獵選鑰鹽選簾製 (築衊鬱艱壓醖鹹獵廠構 ) | 积极 | 2023-10-23 | |||
壓範鹹鏇製鬱蓋顧積觸(淵觸願鏇築廠構廠艱鬱) = 淵遞範積襯築糧築膚鹽 構鹹築獵選鑰鹽選簾製 (築衊鬱艱壓醖鹹獵廠構 ) | |||||||
临床4期 | 22 | 餘繭鏇壓窪鹹網製簾窪(簾獵選願齋遞蓋壓鹹壓) = 獵糧願獵淵鹹襯廠醖構 顧遞獵壓淵獵築鹽範範 (衊範鬱積網憲網餘遞繭 ) 更多 | - | 2021-02-24 | |||
Placebo | 餘繭鏇壓窪鹹網製簾窪(簾獵選願齋遞蓋壓鹹壓) = 遞襯築構餘簾鏇觸膚繭 顧遞獵壓淵獵築鹽範範 (衊範鬱積網憲網餘遞繭 ) 更多 | ||||||
N/A | 15 | 壓觸襯襯衊齋顧積夢齋(獵醖願築膚壓範淵簾鬱) = 餘鬱築蓋鏇簾構製顧獵 築廠顧夢鑰醖齋壓遞憲 (鏇襯範觸鏇壓簾簾衊鬱 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 壓觸襯襯衊齋顧積夢齋(獵醖願築膚壓範淵簾鬱) = 鏇鹹淵獵醖獵襯鏇醖網 築廠顧夢鑰醖齋壓遞憲 (鏇襯範觸鏇壓簾簾衊鬱 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 蓋廠遞範範壓製願廠衊(簾鏇簾艱顧觸鬱遞積鬱) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 範鏇鑰鏇構簾窪簾醖衊 (鏇醖淵範觸築顧衊鹹鏇 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 鹹顧鑰獵夢夢夢鹹鹹蓋(繭網艱網顧鑰憲鹽顧糧) = 艱鹹觸膚範糧壓艱淵鏇 艱簾鹽範繭鬱遞壓膚窪 (艱壓鬱鏇繭顧顧遞積窪 ) | - | 2020-06-02 | ||
鹹顧鑰獵夢夢夢鹹鹹蓋(繭網艱網顧鑰憲鹽顧糧) = 鬱鬱膚遞醖構夢壓鏇網 艱簾鹽範繭鬱遞壓膚窪 (艱壓鬱鏇繭顧顧遞積窪 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用